Facebook Twitter

Moderna’s omicron vaccine booster didn’t protect any better than the normal vaccine in a small study

Moderna’s vaccine that targets the omicron variant might not be any stronger than its normal COVID vaccine

SHARE Moderna’s omicron vaccine booster didn’t protect any better than the normal vaccine in a small study
Worker uses Moderna COVID-19 vaccine.

In this March 29, 2021, file photo, a worker readies syringes with the Moderna COVID-19 vaccine in Metairie, La.

Gerald Herbert, Associated Press

An omicron-specific COVID-19 vaccine did not offer better protection against the omicron variant compared to Moderna’s currently, highly-effective booster shot, according to a new study from researchers at the National Institutes of Health.

  • The study — which was posted ona preprint serverahead of peer review — analyzed the effects of Moderna’s omicron-specific vaccine on a small group of monkeys.

What they found: “The nonhuman primate (NHP) model has ... been largely predictive for what has been observed in humans in terms of protective efficacy,” the authors wrote, according to Ars Technica.

  • The researchers found boosting monkeys with either the omicron-specific vaccine or the normal booster shot led to the same increase in antibodies.
  • “And, when the vaccinated and boosted monkeys were challenged with an omicron infection, both boosters protected the primates equally well from disease in their lower airways,” according to Ars Technica.
  • Scientists expect this finding to hold up in human trials.

Why this matters: This early result should be a sign of what’s to come when Moderna starts to test its omicron-specific vaccine on humans.


The bigger picture: A recent study from Duke University found that the Moderna COVID-19 booster shot created omicron-fighting antibodies that lasted for about six months before decreasing, a sign that the immunity to omicron may only last for half of a year.

  • “The drop in antibodies for the booster is very similar to the drop in antibodies to the delta variant that was noted six months after the second dose of the vaccine,” said co-corresponding author and researcher David Montefiori, according to WRAL.